GlassScriptPhysician profile
Christopher V Nguyen
NPI 1003825035
$9,535.98
in general payments reported to CMS, 2019-2025
29 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $694 · 2021: $386 · 2022: $2,054 · 2023: $1,998 · 2024: $1,843 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,158.95 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,151.92 | 2019-2022 | |
| Medtronic, INC. | $1,784.92 | 2022-2025 | Venaseal, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $1,551.02 | 2020-2025 | |
| Abbott Laboratories | $1,504.20 | 2019-2025 | Confirm Rx, Gallant, Assurity |
| Davol INC. | $266.01 | 2022 | |
| Amgen INC. | $254.13 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $235.42 | 2020-2025 | Watchman Flx, Bodyguardian |
| Acutus Medical, INC. | $210.16 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $158.08 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $154.59 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $131.27 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $120.72 | 2023-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $120.20 | 2022-2023 | Arcalyst |
| Pfizer INC. | $112.03 | 2022-2024 | |
| Baxter Healthcare | $111.60 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107.91 | 2022-2024 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $106.07 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $92.63 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Impulse Dynamics (USA) INC. | $86.04 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $72.71 | 2024 | Assure Wcd |
| Ucb, INC. | $33.99 | 2023 | Fintepla |
| Regeneron Healthcare Solutions, INC. | $29.67 | 2024 | Dupixent |
| Agepha Pharma Fz LLC | $24.83 | 2024 | Lodoco |
| Scpharmaceuticals INC. | $22.83 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.01 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.83 | 2023 | Lifevest |
| Medtronic Vascular, INC. | $18.74 | 2019 | |
| Organogenesis INC. | $17.47 | 2025 | Simplimax |
| Sanofi-Aventis U.S. LLC | $14.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.